Protocol · Mitochondrial/Genetic Disorders
Kearns-Sayre Syndrome Supportive Care Protocol
Coenzyme Q10 and L-Carnitine are the core of this stack, with 5 supporting supplements. Each row gives the amount the protocol lists and the grade our evidence database holds for that supplement in Kearns-Sayre Syndrome Supportive Care.
We are re-verifying the studies cited on protocol pages; only confirmed citations are shown.
The stack
7 supplements · 1 graded
| Grade | Supplement | Amount listed | Why it’s in the stack | Evidence on file |
|---|---|---|---|---|
| Primary stackThe core of this protocol | ||||
| Coenzyme Q10 | Amount listed: 100–600 mg daily (often higher doses used in mito disease) | Essential electron carrier in respiratory chain; supports mitochondrial function; most studied supplement for KSS | Not graded yet | |
| L-Carnitine | Amount listed: 30–100 mg/kg/day in divided doses | Supports fatty acid transport into mitochondria; often deficient in mitochondrial disease | Not graded yet | |
| Supporting stackListed as additions to the core | ||||
| B-Complex Vitamins | Amount listed: High-potency B-complex with extra riboflavin (B2) and thiamine (B1) | Multiple B vitamins are mitochondrial cofactors; supports energy production | Not graded yet | |
| Alpha-Lipoic Acid | Amount listed: 300–600 mg daily | Antioxidant; mitochondrial cofactor; may help reduce oxidative stress | Not graded yet | |
| Creatine | Amount listed: 5–10 g daily | Alternative energy substrate; may help buffer ATP deficiency
| Grade C for Creatinine3 studies · 15 people | |
| Vitamin E | Amount listed: 400–800 IU daily | Antioxidant; helps protect mitochondrial membranes from oxidative damage | Not graded yet | |
| Folinic Acid | Amount listed: 1–5 mg daily (higher doses if CSF folate low) | May help with CNS folate deficiency sometimes seen in KSS | Not graded yet | |
How this protocol works
In plain language
Kearns-Sayre Syndrome (KSS) is a rare mitochondrial disease caused by large deletions in mitochondrial DNA. It typically begins before age 20 and is characterized by a triad of features: progressive external ophthalmoplegia (difficulty moving eyes), pigmentary retinopathy, and heart conduction abnormalities.
CLASSIC TRIAD:
1. Progressive External Ophthalmoplegia (PEO) - weakness of eye muscles causing drooping eyelids and limited eye movement
2. Pigmentary Retinopathy - abnormal pigment deposits in retina
3. Heart Block - often requires pacemaker
OTHER FEATURES:
- Onset before age 20
- Short stature
- Hearing loss
- Ataxia (coordination problems)
- Cognitive decline
- Endocrine problems (diabetes, hypoparathyroidism)
- Muscle weakness
- Swallowing difficulties
CRITICAL: KSS is a serious, progressive condition requiring multidisciplinary specialist care. This protocol is SUPPORTIVE ONLY.
MANAGEMENT PRIORITIES:
- Cardiac monitoring: Regular ECGs; pacemaker often needed for heart block
- Ophthalmology: Monitor vision; ptosis surgery may be needed
- Endocrine: Monitor for diabetes, thyroid, parathyroid dysfunction
- Hearing: Audiological monitoring
- Neurology: Monitor for neurological progression
- Avoid metabolic stressors: Prolonged fasting, extreme temperatures, illness
DRUGS TO AVOID:
- Valproic acid
- Aminoglycoside antibiotics
- Some anesthetics (caution)
CoQ10* is the cornerstone of the "mitochondrial cocktail."
L-Carnitine* helps with fatty acid metabolism and is often deficient.
B vitamins, alpha-lipoic acid, and creatine* provide additional mitochondrial support.
Expected timeline: KSS is progressive. Treatment focuses on managing complications and supporting mitochondrial function. Regular monitoring for cardiac and other complications is essential.